Edwards Lifesciences Q2 sales beat estimates, supported by sustained clinical momentum; shares up

Edwards Lifesciences

23/07/2026 21:26

    

    Overview
  
U.S. heart device maker's Q2 sales rose 13.6%, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year sales growth guidance to 10%-11%
Shares of the company rose about 6.4% in extended trading
 

    

    Outlook
  
Company raises 2026 sales growth guidance to 10%-11% from 9%-11%
Company lifts 2026 TAVR sales growth guidance to 8%-9% from 7%-9%
Edwards sees 2026 adjusted EPS at $2.95-$3.05, unchanged from prior outlook

    

    Result Drivers
  
TAVR GROWTH - Co said TAVR sales rose 11.3% on sustained clinical momentum, new evidence supporting earlier treatment, and the exit of a competitor in Q2 2025
TMTT EXPANSION - Co said TMTT sales grew 47.3% due to increased adoption of its repair and replacement therapies, including PASCAL and EVOQUE systems
SURGICAL ADOPTION - Co said surgical sales rose 6.5% on continued adoption of RESILIA tissue therapies

    
Company press release: ID:nBw7JbdSwa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Sales
Beat
$1.74 bln
$1.70 bln (23 Analysts)
Q2 Adjusted EPS
Beat
$0.78
$0.74 (21 Analysts)
Q2 EPS
 
$0.42
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Edwards Lifesciences Corp is $99.50, about 17.9% above its July 22 closing price of $84.37
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 27 three months ago

    

    Reuters Recommended Reads
  
July 23 - AtriCure Q2 revenue beats estimates
July 23 - Novocure Q2 revenue beats, lifts 2026 outlook
July 20 - Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)